Biological therapies that target IL-6 and its receptor (eg, tocilizumab) are efficacious in RA including for those individuals who do not respond to anti-TNFα treatment.42 43 Although we detected similar concentrations of IL-6 in cocultures, we did observe a different profile of soluble mediators released by resolving and very early RA fibroblast cocultures. Here, IL6 is linked to rheumatoid arthritis.